One moisture-retention endpoint. No comparator values or time-course points are reconstructed here.
Research with a route to value.
We are building a materials R&D company around focused biological programmes, meaningful development problems and the assets useful research could create.
Early-stage research and commercial development. Published research, Bio’s programme plans and calculated business scenarios are distinguished throughout.
Building a materials company around useful biological function.
VARUNÉ Bio is being built at the intersection of biological materials and formulation R&D.
Our initial portfolio has two programmes: polar-associated polymers for a skin-formulation brief, and biochemical light for a separate material-function brief. The commercial ambition is to convert useful research into specifications, methods and technical packages a developer values.
The first asset needs a specific buyer problem, an interpretable comparison and a credible development route. That is the next company-building task.
Development assumptions and rationale
The company opportunity sits between an interesting material and an outcome a developer can reproduce.
A biological origin, a molecular mechanism or a striking demonstration can make a subject worth investigating. A valuable development asset needs more: accountable identity, a useful function, a credible comparison and a way to deliver the result in its intended context.
VARUNÉ Bio is focused on that connection. Our research directions are polar-associated biological materials and biochemical light, with formulation science as the shared approach. Skin formulation is the initial application context for the polar-material question; biochemical light begins with an inert-surface or research-tool question. The longer-term opportunity is to build permissioned knowledge, methods and material specifications that can support further applications when the evidence justifies them.
The ambition is substantial; the route begins with a narrow enough question to answer well.
The problem an R&D team needs to solve.
Our first intended buyer is an ingredient or formulation team facing a consequential performance constraint.
The polar programme gives us a concrete entry point: the behaviour of a deposited topical film alongside application and compatibility requirements. A relevant buyer brief would establish the incumbent, its limitation and the value of a better result.
Buyer need remains a hypothesis to establish through those discussions. We want the development problem to sharpen the science and the commercial case together.
Examine the comparison
| Part of the buyer problem | What needs to become specific |
|---|---|
| Application | The product or material context in which performance matters. |
| Incumbent | The grade, formula or approach already used. |
| Constraint | The limitation that prevents the desired outcome. |
| Value | The development decision a useful result would enable. |
| Sponsor | The person responsible for evaluating and resourcing that decision. |
Development assumptions and rationale
Our first buyer hypothesis is a formulation or ingredient team with a specific performance problem that established options do not adequately resolve.
For the polar-materials direction, a relevant brief could concern water-release behaviour in a topical film, subject to practical constraints such as application behaviour and compatibility. The useful question is whether a defined material contributes an advantage once loading, preparation and the surrounding formula are accounted for.
That is a problem hypothesis to validate with buyers, not evidence of demand already secured. A compelling brief would identify the current comparator, the consequence of its limitation and the decision a better result would unlock.
The commercial test is whether resolving the question is valuable enough for a developer to devote expertise, materials, time or budget to an evaluation.
Three routes into the development chain.
Ingredient suppliers, formulation manufacturers and beauty-group R&D teams could value different parts of the same asset.
A supplier may need a material specification, a manufacturer a repeatable formulation contribution, and a beauty group an advantage that survives qualification. We are interested in the route with the clearest problem, evaluator and development sponsor.
These are prospective buyer categories. The first commercial conversation should identify which decision Bio’s proposed work could help them make.
Examine the comparison
| Prospective buyer | Potential reason to engage | Decision chain to establish |
|---|---|---|
| Personal-care ingredient supplier | Evaluate a differentiated material or formulation contribution. | Application scientist, innovation sponsor and commercial decision maker. |
| Formulation or contract manufacturer | Resolve a recurring formulation problem with a transferable method or system. | Formulation lead, technical director and project sponsor. |
| Beauty-group R&D or external innovation | Assess a useful performance opportunity against an existing development requirement. | Technical evaluator, innovation sponsor and procurement owner. |
Development assumptions and rationale
The first commercial relationships should be selected by problem fit and ability to evaluate the output.
Ingredient suppliers, formulation manufacturers and beauty-group R&D teams can sit at different points in the development chain. A supplier may care about a repeatable material specification; a formulator may care about performance in a particular system; a beauty group may need an advantage that survives product qualification.
These are prospective buyer categories. The technical and budget roles below describe the decision chain to establish in a real conversation; they are not named customers, partnerships or committed opportunities.
Size the opportunity from the material upwards.
Our commercial models follow the output Bio could deliver: a scoped development project, qualified material or useful rights package.
Supply economics begin with adopting accounts, formulations, finished-product volume, inclusion and net material price. Co-development begins with a real scope and delivery contribution. Licensing begins with a technical package and terms a counterparty values.
We will assess each route on its own assumptions and evidence. The models below explain that logic without assigning Bio a revenue forecast or valuation.
Examine the comparison
| Route | Bottom-up model | Inputs that need evidence |
|---|---|---|
| Material supply | Adopting accounts x relevant SKUs x annual units x product mass x inclusion fraction x net price per kg. | Qualified applications, effective inclusion level, adoption, volume and net price. |
| Co-development | Accepted project fees less delivery labour, external work and direct project costs. | Real scope, capacity, quotations, acceptance and payment terms. |
| Licensing | Contracted upfront and achieved milestone payments, plus agreed royalties on a defined base. | Title, useful evidence, permitted rights and negotiated terms. |
Development assumptions and rationale
An addressable market should reflect what Bio could supply or license, rather than the entire retail value of skin care.
For a material-supply route, the calculation begins with relevant accounts and formulations, their finished-product volume and the amount of material required. Net realised price and the cost of delivering qualified material determine how much of that opportunity could become company value.
For co-development, the unit is a scoped project and its delivery contribution. For licensing, it is a useful rights package and the terms a counterparty is willing to agree. These routes require different evidence and should not be added together as if every customer automatically pays for all three.
The model below is the structure for testing the opportunity. It is not a market-size or revenue forecast.
A potential advantage, with a defined use.
A defined application, a credible comparison and an asset with a route to transfer.
Making the difference consequential to a developer.
Our research briefs are designed around an advantage that survives the relevant alternative.
For polar materials, the comparison must account for solids, viscosity and co-extractives. For biochemical light, an architecture must offer a useful balance of retention, access and output beside another practical approach.
The published kinetics below illustrate why development choices depend on context. They inform the questions we ask; they are external results rather than Bio performance data.
Examine the comparison
| Direction | Proposed value | Competing explanation or alternative |
|---|---|---|
| Polar-associated materials | Useful ambient-film behaviour attributable to an accountable material. | An established polymer or an ordinary formulation effect explains the result. |
| Biochemical light | A useful balance of catalyst retention, access and measured output. | A different architecture provides a better practical result. |
Development assumptions and rationale
A development opportunity becomes stronger when the proposed advantage survives plausible alternative explanations.
The polar-film hypothesis needs to distinguish a useful contribution from effects attributable to ordinary solids, viscosity or co-extractives. A credible comparison therefore asks both whether performance differs and why that difference occurs.
The biochemical-light hypothesis asks whether keeping an active catalyst associated with a material can coexist with enough operational output for a specified use. The alternative may be that a solution, a released system or a reconstitutable reagent serves the application better.
These are proposed tests of differentiation. The company case strengthens when an advantage is demonstrated under relevant constraints, and should change when the simpler explanation wins.
A sequence change can change the substrate advantage.
Four enzyme variants, two substrates, one matched scale. Examine the reported catalytic efficiency, turnover and Michaelis constant.
Coelenterazine CTZ
n = 3s⁻¹ µM⁻¹
Furimazine FMZ
n = 3s⁻¹ µM⁻¹
The CTZ efficiency ratio is 70 / 4.4 for the triple mutant versus the reference. With FMZ, the corresponding reported means are 28 versus 64. The advantage depends on the reaction context.
External in vitro research. Whiskers show the paper's standard deviations, not confidence intervals. This does not establish performance in Bio's proposed material, ownership of the technology or commercial permission.
Inspect all source values and definitions
kcat is turnover; Km is the Michaelis constant in the reported kinetic model. Km is not automatically a binding affinity. The published kcat/Km column is preserved as reported rather than recalculated from rounded means.
| Variant | substrate | kcat/Km · s⁻¹ µM⁻¹ | kcat · s⁻¹ | Km · µM | Kp · µM |
|---|---|---|---|---|
| NanoLuc CTZ | 4.4 ± 0.2 | 2.48 ± 0.05 | 0.57 ± 0.02 | 0.256 ± 0.005 |
| NanoLuc-Y94A CTZ | 0.06 ± 0.001 | 0.225 ± 0.004 | 3.74 ± 0.09 | 0.79 ± 0.04 |
| NanoLuc-D9R/K89R CTZ | 37 ± 1 | 16.8 ± 0.6 | 0.46 ± 0.01 | 0.163 ± 0.006 |
| NanoLuc-D9R/H57A/K89R CTZ | 70 ± 7 | 40 ± 4 | 0.77 ± 0.07 | 0.23 ± 0.02 |
| NanoLuc FMZ | 64 ± 2 | 7.88 ± 0.03 | 0.123 ± 0.004 | 0.56 ± 0.01 |
| NanoLuc-Y94A FMZ | 0.402 ± 0.006 | 0.519 ± 0.007 | 1.29 ± 0.02 | 0.85 ± 0.02 |
| NanoLuc-D9R/K89R FMZ | 33 ± 2 | 5.2 ± 0.1 | 0.157 ± 0.009 | 0.39 ± 0.03 |
| NanoLuc-D9R/H57A/K89R FMZ | 28 ± 1 | 2.74 ± 0.03 | 0.098 ± 0.005 | 0.34 ± 0.02 |
Source-table clarification: The CTZ triple-mutant row reports turnover 40 s⁻¹, Km 0.77 µM and efficiency 70 s⁻¹ µM⁻¹. Dividing the first two reported means gives about 51.95, not 70. The published columns are retained pending clarification; exact magnitude should not be treated as independently resolved.
Our starting position. Our next evidence.
We have defined the programme questions and their literature-based comparative briefs.
Bio’s development includes internal and external recruitment and confidential research arrangements. The next packages need to establish the project responsibilities, inputs, permissions and interpretable technical evidence.
Original Bio results will be identified as such when available and permitted for publication. The external endpoint below shows both the appeal of a lead and the further work needed before it can support a formulation asset.
Examine the comparison
| Evidence category | What this page establishes | What it does not establish |
|---|---|---|
| Research direction | Two defined directions and their scientific questions. | A successful company experiment or a validated product. |
| Scientific rationale | Literature-based arguments and proposed comparisons. | Independent human review of every company paper. |
| Organisation | Internal recruitment and external arrangements, with identities confidential. | A disclosed headcount, facility inventory or delivery-capacity claim. |
| Commercial route | A proposed sequence of evaluation, development and possible exploitation. | A customer contract, revenue forecast or confirmed buyer demand. |
Development assumptions and rationale
The documented starting point is literature-led programme definition and a set of comparative research questions.
The programme materials set out candidate reasoning, proposed comparisons and the limits of what the literature establishes. They provide a basis for technical challenge and work-package definition. They are not reports of Bio’s own experimental performance.
Internal and external recruitment and research arrangements form part of the company’s development, with identities remaining confidential. The exact responsibilities, availability and rights needed for a particular project belong in that project’s diligence.
The next increase in confidence must come from evidence appropriate to the risk: interpretable technical data, a workable rights position, an executable scope or a specific buyer requirement.
A promising endpoint. A demanding transfer question.
Reported moisture retention for a Polaribacter sp. SM1127 EPS preparation after 72 hours.
Percentage of starting water remaining
- Observation
- 72 hours
- Temperature
- 25 °C
- Reported environment
- Silica-gel chamber
- Test
- Gravimetric retention
The methods also mention 43% RH; the results and Fig. 3c state a silica-gel chamber. The moisture method refers to crude EPS. Resolve both before reproducing the test.
A defined preparation, ordinary formulation effects, a deposited layer and relevant environmental conditions. A bulk result does not establish a skin outcome.
External preparation-specific research, not Bio data. Characterisation of purified EPS must not be silently assigned to a crude preparation. No clinical or product claim is implied.
Source-condition clarification: Resolve the paper’s retention-condition discrepancy first: Results/Figure 3c specify silica gel; the method also mentions 43% RH. Then pre-specify a gravimetric test with matched solids, starting water, environmental control, benchmark and independent preparations.
Co-development first. Supply or licensing when justified.
Our intended entry route is a scoped feasibility or co-development engagement around a real R&D problem.
The first engagement would deliver defined work and an informative development decision, with scope, scientific responsibility, access and cost established for the package.
A useful and reproducible asset could support supply or licensing later. The route should follow the evidence, retained rights and delivery economics of that particular asset.
Examine the comparison
| Possible step | Value delivered | Requirement before advancing |
|---|---|---|
| Feasibility or co-development | A defined question, comparative evidence and a decision. | Credible scope, delivery capacity, rights and cost. |
| Material or formulation supply | Consistent qualified output with relevant support. | Specification, reproducibility, manufacture and workable economics. |
| Licensing | Permission to use a useful technical package. | Clear title, transferable knowledge and negotiated exploitation terms. |
Development assumptions and rationale
The proposed first route is a bounded feasibility or co-development engagement around a real buyer problem.
That route becomes credible when the scientific responsibility, capacity, permitted inputs, costs and intended output are clear. The buyer pays for defined work and an informative decision; a favourable scientific result cannot be guaranteed.
If the work establishes a useful, reproducible asset, supply or licensing may become appropriate. The choice depends on what has been created, who controls the relevant rights, how it can be delivered and where the economics are strongest.
This is the commercial sequence under consideration. A discussion of fit comes before an offer, and the terms must preserve a sensible balance between the partner’s needs and the knowledge Bio can carry into future work.
A stronger next decision.
Research value grows when the result changes the buyer’s or partner’s next commitment.
A formulation-scale business has to work in kilograms.
The model makes adoption, inclusion, price and contribution visible enough to challenge.
Use the illustrative scenario to examine how a supply route would behave under different assumptions. Every input is hypothetical; the purpose is to expose the variables that real development and buyer evidence must establish.
Lower inclusion or fewer buyers can sharply reduce captured value. The next commercial case should survive those sensitivities alongside manufacturing, qualification and working-capital requirements.
Examine the comparison
| Illustrative case only | Material volume | Net sales at £400/kg | Variable contribution at £150/kg |
|---|---|---|---|
| 20 accounts; assumed 0.5% inclusion | 1,000 kg | £400,000 | £150,000 |
| 2 accounts; otherwise unchanged | 100 kg | £40,000 | £15,000 |
| 20 accounts; assumed 0.1% inclusion | 200 kg | £80,000 | £30,000 |
Development assumptions and rationale
An attractive ingredient story still has to work at the level of units, kilograms and contribution.
Consider a wholly hypothetical supply scenario: 20 adopting accounts, each with two products selling 100,000 units annually. At 50 g per product and an assumed 0.5% inclusion, those four million finished units would require 1,000 kg of material. These are illustrative inputs, not Bio demand, a recommended dose or a forecast.
At a hypothetical gross price of £500/kg and 80% net realisation after included channel deductions, net price would be £400/kg. If variable cost were £250 per saleable kilogram, the resulting variable contribution would be £150/kg. Fixed costs, research, capital and any omitted costs would still need to be funded.
The same arithmetic makes the sensitivity clear. Fewer adopting accounts or a lower effective inclusion level can reduce captured value sharply. Real pricing, dose, costs and adoption must come from evidence rather than making the model fit a desired valuation.
The economics must survive a lower dose or fewer buyers.
Change the adoption, inclusion, price and cost inputs. This models a possible ingredient-supply route; it is not Bio demand, a recommended dose, a revenue forecast or a valuation.
Product and volume assumptions
Annual volume is assumed to be fully adopted and sold. Price and cost are hypothetical. Taxes, timing, working capital, development, capital expenditure and costs outside the entered allowance are excluded.
Enter a value within each labelled range. Results retain the last valid scenario until all inputs are valid.
Uses positive unit contribution of £150/kg and the entered £100,000 annual allowance. It is not an overall company break-even calculation.
Adoption × inclusion
Annual amount remaining after the entered fixed allowance. Select a cell to inspect that scenario.
Inclusion →0.1%0.25%0.5%1%25102040
Variable contribution = volume × (net material price − variable cost per saleable kg). Remaining amount deducts only the entered fixed allowance. Paid development and licensing require separate models; adding their revenues here would risk double counting.
Inspect the selected scenario record
{
"kind": "Illustrative supply scenario; not a Bio forecast or valuation",
"version": 1,
"currency": "GBP",
"inputs": {
"accounts": 20,
"skus": 2,
"units": 100000,
"massG": 50,
"dosePercent": 0.5,
"grossPrice": 500,
"realisationPercent": 80,
"variableCost": 250,
"fixedCost": 100000
},
"outputs": {
"perAccountKg": 50,
"kg": 1000,
"netPrice": 400,
"unitContribution": 150,
"sales": 400000,
"variableSpend": 250000,
"contribution": 150000,
"remaining": 50000,
"breakEvenKg": 666.6666666666666,
"breakEvenAccounts": 14
},
"exclusions": [
"Unentered costs",
"Taxes",
"Timing",
"Working capital",
"Development",
"Capital expenditure"
],
"createdAt": "2026-10-30T11:05:56.760Z"
}Building an asset with a clear basis for control.
The potential advantage may combine a specification, transferable method, permissioned data and retained know-how.
We want the asset record to connect useful performance with what Bio can legitimately use, transfer or protect. Material provenance, project agreements and technology permissions are part of that development work.
No Bio patent, exclusive licence or freedom-to-operate conclusion is asserted here. Those rights need their own documented basis in diligence.
Examine the comparison
| Potential source of defensibility | Evidence needed |
|---|---|
| A reproducible specification | Identity, controlled variation and useful performance. |
| A transferable method | Documented process, repeatability and permitted use. |
| A valuable dataset | Provenance, quality, access rights and relevance to a decision. |
| Protected or retained know-how | Clear title, confidentiality discipline and practical value to a counterparty. |
Development assumptions and rationale
A valuable asset may combine a specification, a method, permissioned data and know-how that is difficult to reproduce.
The relevant question is what Bio can legitimately control, transfer and use to deliver value. An idea in a paper, a purchased research material and an owned commercial asset are different things.
Material provenance and use permissions need to match the intended activity. Genetic-resource requirements can depend on the source and circumstances of access. Established research technologies may also have a separate licensing route. Neither a publication nor purchase alone resolves all of those questions.
For diligence, the useful record separates each asset, its evidence, the rights relied upon and the remaining restrictions. This page does not claim that a Bio patent, exclusive material licence or freedom-to-operate conclusion has been established.
Organise the company around the next milestone.
We are building the programme responsibilities around the expertise the work requires.
Polymer and formulation reasoning, material characterisation, enzyme science and optical measurement contribute differently to the two programmes. Each package needs accountable interpretation and an appropriate technical review.
Internal recruitment and external research arrangements remain confidential where required. Availability, access and delivery responsibilities should be established for the specific scope under discussion.
Examine the comparison
| Work to accomplish | Competence to establish in diligence |
|---|---|
| Accountable material selection | Composition, preparation, provenance and analytical interpretation. |
| A meaningful film comparison | Formulation, polymer behaviour and appropriate measurement. |
| An informative light-material comparison | Enzyme activity, material transport and optical measurement. |
| A usable development decision | Scientific challenge, rights, cost and application judgement. |
Development assumptions and rationale
The research organisation needs to be assessed against the work it must perform.
Bio’s development includes internal recruitment and external research arrangements. Identities remain confidential. A credible evaluation still needs to establish who is accountable for each technical decision and which capabilities are available for the proposed scope.
The polar and biochemical-light directions require overlapping formulation reasoning but distinct specialist contributions. Confidence comes from matching those contributions to a defined output and a qualified review, rather than assuming a broad scientific title covers every task.
Invest in the evidence that unlocks the next commitment.
Our proposed milestone sequence connects scientific outputs with company decisions.
A defined buyer brief establishes relevance. Accountable inputs and permissions enable the comparison. Feasibility and repeatability determine whether there is an asset to evaluate. A scoped commercial assessment tests the route forward.
Budgets and timing will follow the actual package. The planning calculator below makes one part of that burden visible: the independent-unit count implied by an assumed variability and target effect.
Examine the comparison
| Proposed milestone | Risk it should reduce | Decision it enables |
|---|---|---|
| Defined buyer problem and target profile | Unclear relevance to a real development need. | Select a problem worth a bounded evaluation. |
| Accessible, accountable input and permissions | Unusable material or rights position. | Proceed with an interpretable comparison. |
| Comparative feasibility result | No useful advantage or unresolved confounding. | Advance, change the question or stop. |
| Repeatability and application assessment | A result that fails outside its first configuration. | Evaluate a transferable asset. |
| Scoped commercial evaluation | No workable route from evidence to a buyer decision. | Choose whether supply, licensing or further development is justified. |
Development assumptions and rationale
The most useful milestone reduces a specific uncertainty and makes the next commitment easier to judge.
A programme can consume time without changing its investment case. The proposed sequence links each output to the decision it should support: whether the input is usable, whether an advantage exists, whether it survives transfer and whether a buyer can evaluate it.
Budgets and timing need to follow the actual material, methods, permissions and delivery plan. The table describes a development logic, not a funded schedule or a list of completed milestones.
A small effect can require a much larger experiment.
Explore the independent-unit count implied by variability and the effect worth detecting. Two equal independent groups; two-sided α = 0.05; 80% power; known equal variance and a normal approximation.
32 total
Replication means an independent unit.
Repeated readings from one preparation do not create independent batches. Blocking, batch effects and multiple comparisons change the design.
Variability is not uncertainty in the mean.
SD describes spread. SE = SD / √n describes precision under the assumptions. A confidence interval needs a justified sampling model and critical value.
The curve is an unrounded calculation; the displayed count rounds upwards. This two-group expression follows from the variance of an independent mean difference, 2σ²/n. NIST describes the one-process normal-approximation basis. Estimated variance, small samples, non-normal outcomes or nested replicates need a tailored analysis. This is not a Bio protocol, budget or experimental result.
The decisive challenge: can the work become a repeatable asset?
We want to build beyond individual projects while retaining the discipline to recognise a narrower opportunity.
The strongest challenges are clear: an incumbent may be sufficient, a result may fail to transfer, rights or process costs may constrain development, or the buyer may not value the output.
Our next evidence should address those challenges directly. A useful specification and repeatable development route would strengthen the company case; bespoke work alone would call for a different business assessment.
Examine the comparison
| Objection | Evidence that would change the assessment |
|---|---|
| Existing alternatives are sufficient. | A relevant advantage that survives a fair comparison and practical constraints. |
| The company becomes a project consultancy. | Retained, permissioned knowledge or assets with a credible route to reuse. |
| The result cannot be delivered economically. | Reproducibility, process and cost evidence matched to a plausible price and volume. |
| The buyer does not value the result. | A specific evaluation requirement and a sponsor willing to resource the decision. |
Development assumptions and rationale
Scientific interest alone does not establish a scalable company.
The strongest objection is that established materials may already solve the relevant problem, or that each engagement may remain bespoke work with limited reusable value. Another is that rights, reproducibility or scale costs could make an attractive result commercially unusable.
Those objections define the tests the company should welcome. A fair incumbent comparison challenges differentiation. A buyer specification challenges relevance. A costed delivery plan challenges the economics. A rights review challenges what can actually be exploited.
If the evidence supports only a narrow service opportunity, that should be recognised. If it supports a useful repeatable asset, the company can make a stronger case for further investment. Protecting the preferred narrative is not the objective.
Let each milestone earn the next investment.
Our capital approach is to cost a complete research package and commit against the decision it can resolve.
That includes the necessary capability, inputs, permissions and review. Biochemical light has its own application and resource case; the portfolio should remain focused enough for each programme to receive an accountable decision.
Funding is a route to explore, rather than cash assumed to be available. The operating case must stand on the scope and resources that can actually be established.
- Choose an output that can change a scientific or commercial decision.
- Cost the complete scope, including dependencies and appropriate review.
- Retain the ability to stop when the result or economics do not justify continuation.
- Expand the commitment when the evidence supports the next level of risk.
Development assumptions and rationale
Each commitment should be proportionate to the uncertainty it can resolve.
The proposed approach is to define and cost a bounded question, resolve the necessary permissions, and commit to the next package when the evidence supports it. Access to the right capability matters more at this stage than a narrative about owning extensive infrastructure.
Biochemical light needs its own application and spending decision; it should not inherit an unlimited budget from its visual appeal. A useful demonstrator must still fit a practical use and an acceptable development burden.
Prospective funding is a possible route, not cash available to spend. The operating plan needs to remain understandable without an assumed grant, a premature product launch or an unverified licensing deal.
Discuss the company we are building.
We welcome investors who want to connect a demanding scientific brief with a credible route to company value.
A first discussion can examine the intended buyer, the strongest external basis, the next technical milestone and the resources needed to reach it. Deeper diligence can follow around the relevant records and confidentiality arrangements.
Bring your investment focus and the question you would need Bio to answer next. The aim is a concrete development or diligence step with a clear purpose.
Examine the comparison
| First-meeting question | Useful output |
|---|---|
| What problem is the company choosing first? | A common understanding of buyer and application. |
| What is the strongest evidence and the largest uncertainty? | A prioritised diligence question. |
| What would the next commitment establish? | A milestone with a decision, dependencies and evidence requirements. |
| Is there a fit for deeper discussion? | A scoped follow-up, a revisit point or a reasoned decline. |
Development assumptions and rationale
A productive investor meeting should identify the most important question to investigate next.
The starting discussion is the company thesis: the first buyer problem, the strongest available evidence, the execution requirements and the next value-changing milestone. The same scientific record should support both the commercial story and the technical questions.
For a relevant investor, deeper diligence can then be scoped around the actual records and the permissions that govern them. That may involve the scientific basis, programme responsibilities, material rights, buyer evidence or a costed work plan. Confidential information needs an agreed route; its existence or availability should never be assumed.
Share your investment focus and the question you would want a first meeting to resolve. The useful outcome is a defined next step, a milestone to revisit, or a clear decision that the fit is not right.
The investment perspective.
Discuss the investment case
A short, non-confidential introduction can outline the application, the current approach, and where scientific input could help. Scope and next steps would be agreed around the actual project.
Prepare an investment discussionSources and reading notes.
External work is identified below. Access notes describe the material inspected for this page; company research questions and proposed work are not presented as findings from these sources.
NIST/SEMATECH, n.d.NIST/SEMATECH Engineering Statistics Handbook, Choosing an experimental design
Design selection, factors, blocking and replication as foundations for interpretable comparisons.
Scope and limitations: Handbook index and selected randomisation/design-principle sections inspected. Specific experimental design and sample-size calculations require an accountable statistician; this is not a Bio protocol.
Open original sourceGOV.UK, n.d.GOV.UK: Nagoya Protocol access and benefit sharing
Fetched 6 October 2026. Material-specific access, provenance and due-diligence applicability conditions.
Scope and limitations: Does not determine obligations for an unidentified material or prove any Bio access/compliance status; other relevant regimes require separate assessment.
Open original sourcePromega, n.d.Promega technology licensing opportunities
Fetched official licensing page 6 October 2026; supports a distinct technology-licensing route to investigate.
Scope and limitations: Not the exact product licence or permission for a Bio experiment, service or sale. Exact construct/product, current terms and activity need separate review.
Open original sourceSequoia Capital, n.d.Sequoia Capital: Writing a Business Plan
Fetched 6 October 2026. Investor-authored framework covering purpose, problem, alternatives, market, business model, team and vision.
Scope and limitations: General guidance, not a Bio assessment, investment commitment or verified investor fit.
Open original sourceNemergut et al., 2023Nemergut et al. (2023): NanoLuc kinetic parameters, Table 1
Eight reported kinetic rows, preserved means and SDs, n=3, matched CTZ/FMZ comparison.
Scope and limitations: External in vitro work. No raw replicates reconstructed; no Bio material performance, technology ownership or licence established.
Open original sourceSun et al., 2015Sun et al. (2015): SM1127 EPS moisture retention, Fig. 3c and methods
The explicit 75.79 +/- 2.5% 72-hour endpoint, triplicate SD, 25 degrees C; results/methods environment discrepancy and crude-EPS boundary.
Scope and limitations: No comparator values or time course inferred. Bulk preparation experiment, not a deposited film, skin outcome or Bio result; method clarification and human scientific review needed.
Open original sourceNIST/SEMATECH, n.d.NIST/SEMATECH: Sample sizes required
Normal-approximation assumptions, alpha, power and variability in sample-size planning; Bio page derives the two-group extension from independent mean-difference variance.
Scope and limitations: Illustrative calculation, not an experimental protocol or statistical review. Small samples, estimated variance, batch structure and multiple testing require an appropriate analysis.
Open original source
Film credits

